Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner) in the context of dementia, alzheimer's & cognitive decline, published as a randomized controlled trial.

Hydromethylthionine mesylate (HMTM) targets tau pathology and has tau-independent symptomatic activity.

Who Took Part

The age groups tagged for this paper are older adults, both men and women.

Biomarker outcomes included change in plasma levels of neurofilament light chain (NfL), pTau217 and MRI measures of grey matter atrophy.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

82 centres in Canada, European Union, United Kingdom and United States of America.

What Was Measured

Topics PubMed links to this paper include Cognitive Dysfunction, Alzheimer Disease, Biomarkers, tau Proteins, Phenothiazines and Methylene Blue.

The authors tagged it with the keywords Alzheimer’s disease, Hydromethylthionine mesylate, Neurofilament light chain, Phosphorylated-tau 217 and Tau aggregation inhibitor.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in people with dementia, alzheimer's & cognitive decline.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (The journal of prevention of Alzheimer's disease), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, Dementia, Alzheimer's & cognitive decline research.